Literature DB >> 23954947

The role of chemokines in acute and chronic hepatitis C infection.

Stephen Fahey1, Eugene Dempsey2, Aideen Long1.   

Abstract

Hepatitis C imposes a significant burden on global healthcare. Chronic infection is associated with progressive inflammation of the liver which typically manifests in cirrhosis, organ failure and cancer. By virtue of elaborate evasion strategies, hepatitis C virus (HCV) succeeds as a persistent human virus. It has an extraordinary capacity to subvert the immune response enabling it to establish chronic infections and associated liver disease. Chemokines are low molecular weight chemotactic peptides that mediate the recruitment of inflammatory cells into tissues and back into the lymphatics and peripheral blood. Thus, they are central to the temporal and spatial distribution of effector and regulatory immune cells. The interactions between chemokines and their cognate receptors help shape the immune response and therefore, have a major influence on the outcome of infection. However, chemokines represent a target for modulation by viruses including the HCV. HCV is known to modulate chemokine expression in vitro and may therefore enable its survival by subverting the immune response in vivo through altered leukocyte chemotaxis resulting in impaired viral clearance and the establishment of chronic low-grade inflammation. In this review, the roles of chemokines in acute and chronic HCV infection are described with a particular emphasis placed on chemokine modulation as a means of immune subversion. We provide an in depth discussion of the part played by chemokines in mediating hepatic fibrosis while addressing the potential applications for these chemoattractants in prognostic medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23954947      PMCID: PMC4002142          DOI: 10.1038/cmi.2013.37

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  185 in total

1.  Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C.

Authors:  F Kusano; Y Tanaka; F Marumo; C Sato
Journal:  Lab Invest       Date:  2000-03       Impact factor: 5.662

2.  An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region.

Authors:  Tatsunori Nakano; Gillian M G Lau; Grace M L Lau; Masaya Sugiyama; Masashi Mizokami
Journal:  Liver Int       Date:  2011-12-05       Impact factor: 5.828

Review 3.  Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles.

Authors:  Kenneth J Simpson; Neil C Henderson; Cynthia L Bone-Larson; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel
Journal:  Clin Sci (Lond)       Date:  2003-01       Impact factor: 6.124

4.  VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues.

Authors:  Muriel Mathonnet; Bernard Descottes; Denis Valleix; François Labrousse; Yves Denizot
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

5.  Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.

Authors:  Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

6.  Comprehensive assessment of chemokine expression profiles by flow cytometry.

Authors:  Jens Eberlein; Tom T Nguyen; Francisco Victorino; Lucy Golden-Mason; Hugo R Rosen; Dirk Homann
Journal:  J Clin Invest       Date:  2010-02-08       Impact factor: 14.808

Review 7.  Chemoattractant receptor signaling and the control of lymphocyte migration.

Authors:  John H Kehrl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 8.  Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity.

Authors:  Tatsuya Kanto; Norio Hayashi
Journal:  Intern Med       Date:  2006-03-15       Impact factor: 1.271

9.  Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation.

Authors:  Karla J Helbig; Andrew Ruszkiewicz; Ljiljana Semendric; Hugh A J Harley; Shaun R McColl; Michael R Beard
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

10.  Hepatitis C virus proteins interfere with the activation of chemokine gene promoters and downregulate chemokine gene expression.

Authors:  Maarit Sillanpää; Pasi Kaukinen; Krister Melén; Ilkka Julkunen
Journal:  J Gen Virol       Date:  2008-02       Impact factor: 3.891

View more
  26 in total

1.  Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Authors:  S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens
Journal:  Aliment Pharmacol Ther       Date:  2015-08-28       Impact factor: 8.171

Review 2.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

Review 3.  Interplay between phosphoinositide lipids and calcium signals at the leading edge of chemotaxing ameboid cells.

Authors:  Joseph J Falke; Brian P Ziemba
Journal:  Chem Phys Lipids       Date:  2014-01-19       Impact factor: 3.329

Review 4.  Immune Cell Trafficking to the Liver.

Authors:  Sulemon Chaudhry; Jean Emond; Adam Griesemer
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

Review 5.  Cellular and molecular regulation of innate inflammatory responses.

Authors:  Juan Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2016-10-31       Impact factor: 11.530

6.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

7.  CMI: Highlights in last three years.

Authors:  Zhi-Qing Hu
Journal:  Cell Mol Immunol       Date:  2016-08-29       Impact factor: 11.530

8.  Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C.

Authors:  Zhen-Qi Han; Tao Huang; Yong-Zhi Deng; Guang-Ze Zhu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases.

Authors:  Akiko Eguchi; Ariel E Feldstein
Journal:  Liver Res       Date:  2018-02-28

Review 10.  An insight into the diagnosis and pathogenesis of hepatitis C virus infection.

Authors:  Mohammad Irshad; Dhananjay Singh Mankotia; Khushboo Irshad
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.